Systematic Review of Infrapopliteal Drug-Eluting Stents: A Meta-Analysis of Randomized Controlled Trials
- 695 Downloads
Drug-eluting stents (DES) have been proposed for the treatment of infrapopliteal arterial disease. We performed a systematic review to provide a qualitative analysis and quantitative data synthesis of randomized controlled trials (RCTs) assessing infrapopliteal DES.
Materials and Methods
PubMed (Medline), EMBASE (Excerpta Medical Database), AMED (Allied and Complementary medicine Database), Scopus, CENTRAL (Cochrane Central Register of Controlled Trials), online content, and abstract meetings were searched in September 2012 for eligible RCTs according to the preferred reporting items for systematic reviews and meta-analyses selection process. Risk of bias was assessed using the Cochrane Collaboration’s tool. Primary endpoint was primary patency defined as absence of ≥50 % vessel restenosis at 1 year. Secondary outcome measures included patient survival, limb amputations, change of Rutherford–Becker class, target lesion revascularization (TLR) events, complete wound healing, and event-free survival at 1 year. Risk ratio (RRs) were calculated using the Mantel–Haenszel fixed effects model, and number-needed-to-treat values are reported.
Three RCTs involving 501 patients with focal infrapopliteal lesions were analyzed (YUKON-BTX, DESTINY, and ACHILLES trials). All three RCTs included relatively short and focal infrapopliteal lesions. At 1 year, there was clear superiority of infrapopliteal DES compared with control treatments in terms of significantly higher primary patency (80.0 vs. 58.5 %; pooled RR = 1.37, 95 % confidence interval [CI] = 1.18–1.58, p < 0.0001; number-needed-to-treat (NNT) value = 4.8), improvement of Rutherford–Becker class (79.0 vs. 69.6 %; pooled RR = 1.13, 95 % CI = 1.002–1.275, p = 0.045; NNT = 11.1), decreased TLR events (9.9 vs. 22.0 %; pooled RR = 0.45, 95 % CI = 0.28–0.73, p = 0.001; NNT = 8.3), improved wound healing (76.8 vs. 59.7 %; pooled RR = 1.29, 95 % CI = 1.02–1.62, p = 0.04; NNT = 5.9), and better overall event-free survival (72.2 vs. 57.3 %; pooled RR = 1.26, 95 % CI = 1.10–1.44, p = 0.0006; NNT = 6.7).
DES for focal infrapopliteal lesions significantly inhibit vascular restenosis and thereby improve primary patency, decrease repeat procedures, improve wound healing, and prolong overall event-free survival.
KeywordsMeta-analysis Systematic review Infrapopliteal Below-the-knee Drug-eluting stents Restenosis Amputation Wound healing Event-free survival risk ratio Randomized controlled trial Sirolimus Everolimus Angioplasty
Critical limb ischemia
Target lesion revascularization
Drug eluting stents
Bare metal stents
Randomized controlled trial
Quantitative vascular angiography
Color doppler ultrasonography
Peak systolic velocity ratio
DerSimonian and Lairdc
Preferred reporting Items for systematic reviews and meta-analyses
Conflict of interest
- 2.Rooke TW, Hirsch AT, Misra S, Sidawy AN, Beckman JA, Findeiss LK et al (2011) 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg 54(5):e32–e58PubMedCrossRefGoogle Scholar
- 3.Katsanos K, Spiliopoulos S, Krokidis M, Karnabatidis D, Siablis D (2012) Does below-the-knee placement of drug-eluting stents improve clinical outcomes? J Cardiovasc Surg (Torino) 53(2):195–203Google Scholar
- 8.Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC et al (2009) Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol 20(9):1141–1150PubMedCrossRefGoogle Scholar
- 9.Karnabatidis D, Spiliopoulos S, Diamantopoulos A, Katsanos K, Kagadis GC, Kakkos S et al (2011) Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. J Endovasc Ther 18(1):1–12PubMedCrossRefGoogle Scholar
- 12.Scheinert D, Katsanos K, Zeller T, Koppensteiner R, Commeau P, Bosiers M et al (2012) A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 60(22):2290–2295PubMedCrossRefGoogle Scholar
- 17.Begg CB (1994) Publication bias. In: Cooper H, Hedges LV (eds) The handbook of research synthesis. Sage, New York, NY, pp 399–409Google Scholar
- 25.Biondi-Zoccai GG, Sangiorgi G, Lotrionte M, Feiring A, Commeau P, Fusaro M et al (2009) Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients. J Endovasc Ther 16(3):251–260PubMedCrossRefGoogle Scholar
- 26.Siablis D, Kraniotis P, Karnabatidis D, Kagadis GC, Katsanos K, Tsolakis J (2005) Sirolimus-eluting versus bare stents for bailout after suboptimal infrapopliteal angioplasty for critical limb ischemia: 6-month angiographic results from a nonrandomized prospective single-center study. J Endovasc Ther 12(6):685–695PubMedCrossRefGoogle Scholar
- 29.Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA et al (2012) Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. Br Med J 345:e5170CrossRefGoogle Scholar
- 32.Rastan A, Brechtel K, Krankenberg H, Zahorsky R, Tepe G, Noory E et al (2012) Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol 60(7):587–591PubMedCrossRefGoogle Scholar
- 35.Alam M, Bandeali SJ, Virani SS, Jneid HM, Shahzad SA, Ramanathan KB et al (2012) Clinical outcomes of percutaneous interventions in saphenous vein grafts using drug-eluting stents compared to bare-metal stents: a comprehensive meta-analysis of all randomized clinical trials. Clin Cardiol 35(5):291–296PubMedCrossRefGoogle Scholar